[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 29,656
Citations 0
JAMA Insights
Clinical Update
July 22, 2020

Lipids and Lipoproteins in 2020

Author Affiliations
  • 1Centre for Naturally Randomized Trials, University of Cambridge, Cambridge, United Kingdom
  • 2Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
  • 3Department of Pharmacological and Biomolecular Sciences, University of Milan and Multimedica IRCCS, Milano, Italy
JAMA. Published online July 22, 2020. doi:10.1001/jama.2020.5685

This JAMA Insights explains how recent studies have clarified the role of lipids and lipoproteins in the development of atherosclerotic cardiovascular disease (ASCVD) and led to changes in clinical practice guidelines for the management of dyslipidemia.1

Cholesterol and triglycerides are the major lipids in humans and are transported in plasma by lipoproteins. A lipoprotein is composed of cholesterol, triglycerides, and a single apolipoprotein B100 molecule (apoB) when secreted into plasma by the liver, and is referred to as a very low-density lipoprotein (VLDL). The triglycerides are rapidly removed by the enzyme lipoprotein lipase and used for energy consumption and storage. As triglycerides are being progressively removed, the lipoprotein is referred to as a VLDL remnant particle. After most of the triglycerides have been removed, the lipoprotein becomes denser and is referred to as a low-density lipoprotein (LDL). However, it is important to recognize that a VLDL particle, a remnant particle, and an LDL particle are merely different names for the same circulating apoB lipoprotein at different stages in its lifecycle, depending on the lipid content that it carries.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Management of Dyslipidemia 2020-21
    Douglas Pfeiffer, D.C. | Center for Nutrition and Wellness
    I found this article to be very informative and useful. I was curious however if it is know what specifically causes the apoB lipoprotein molecule to "flux across the endothelial barrier"? Could this be due to an inflammatory response? I appreciate any insight that you may have regarding the stimulus for this event.